Company: JUNS
Filing Date: 2025-11-26
Form Type: S-1
Source: 0001493152-25-025204
Chunk: 143

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-26
Form: S-1
Chunk 143
---
 US Marketing
approval, to demand that the Company pay a one-time payment of $3 million for reduced royalties of 1.25%. Termination can occur due to
material breach or insolvency, with specific provisions for retaining licenses. Recent amendments include a Debt Forgiveness and Exchange
Agreement on December 1, 2021, where $225,000 of debt was forgiven in exchange for $125,000 cash, a $100,000 promissory note, and stock
options.

The Company relies on trade
secret protection and contractual confidentiality obligations to safeguard certain proprietary know-how related to JOTROL™.
The Company also asserts common law trademark rights in the JOTROL™ name. In January 2025, the Company filed an intent-to-use
trademark application with the U.S. Patent and Trademark Office..

Operating Segments

As of September 1, 2025, the
Company has two operating segments: (i) its premium nutritional supplements, and (ii) pharmaceutical operations focused on drug candidates
for CNS and rare orphan diseases.

PREMIUM NUTRITIONAL SUPPLEMENTS - NUGEVIA BRAND

Overview

In March 2025, the Company
unveiled a major strategic initiative to launch a consumer-focused longevity and wellness product under a wholly-owned subsidiary. The
three core products expected to be launched in Q3 2025 in a DTC model will target the “Beauty from Within” category, mental
wellness and mitochondria support. These products emphasize scientifically backed formulations designed to support longevity and overall
health and are expected to mark the beginning of a growing revenue stream in parallel with the Company’s advancing therapeutic pipeline.

| 80 |

The expansion into longevity
is not only logical, but timely. As outlined in a UBS report dated March 28, 2025 (“UBS Report”), the global longevity market
is projected to grow from $5.3 trillion in 2023 to $8 trillion by 2030. Aging demographics, especially in developed markets, are driving
a surge in demand for products that extend health span and support cognitive vitality, metabolic health and cellular resilience –
all area where JOTROL™ and resveratrol show therapeutic promise.

The Company is well-aligned
with trends highlighted in the UBS report:

| ● | Neuroinflammation and metabolic dysfunction are primary aging 
 accelerators.                                                 |

| ● | The NLRP3 inflammasome, a target of JOTROL™